Previous 10 | Next 10 |
Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...
Ahead of its JPM20 presentation, Invitae (NYSE: NVTA ) announces preliminary 2019 results and its 2020 outlook. More news on: Invitae Corporation, Healthcare stocks news, Read more ...
SAN FRANCISCO , Jan. 12, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2019 results, driving strong growth in volume and revenues, signaling continued momentum going into 2020. The company accessioned...
SAN FRANCISCO , Jan. 8, 2020 /PRNewswire/ -- Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics joined Behind the Seizu...
The genetic testing industry has been synonymous with growth in recent years. Advances in high-volume DNA sequencing, data interpretation, health insurance coverage, and pharmaceutical company partnerships have combined to create profitable businesses with ample long-term growth opportunities. ...
SAN FRANCISCO , Dec. 31, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George , co-founder and chief executive officer of Invitae, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesd...
Invitae (NYSE: NVTA ) announces the launch of Discover Dysplasias, an initiative with BioMarin Pharmaceutical (NASDAQ: BMRN ) to offer genetic testing at no charge to patients with symptoms of having a skeletal dysplasia. More news on: Invitae Corporation, BioMarin Pharmaceutical In...
SAN FRANCISCO , Dec. 10, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™ , an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symp...
Genetic testing services provider Invitae ( NVTA -4.8% ) slips on below-average volume in apparent response to a new (but not yet posted) report from independent research shop Hedgeye that sees a 30 - 50% downside in shares. More news on: Invitae Corporation, Healthcare stocks news, St...
Genetic testing is the study of the cells and tissues contained in the gene to get a better understanding of genetic disorders such as like cancer etc. New genetic testing technologies, together with increasing efficiency and accuracy are providing lucrative growth opportunities for the geneti...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...